Scott Woods, MD

Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study

Background: In the 12-week ARM-TD and AIM-TD studies, the odds of response to deutetrabenazine treatment were higher than the odds of response to placebo at all response levels. Deutetrab...

Hubert Fernandez , MD;

Stewart Factor , DO;

Mat Davis , PhD;

David Stamler , MD;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

William Ondo , MD;

Fredrick Jarskog , MD;

Scott Woods , MD;

Mark LeDoux , MD, PhD;

David Shprecher , DO, MS;

Karen Anderson , MD;

03/01/2019

Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study

Background: Deutetrabenazine was efficacious and safe in treating tardive dyskinesia (TD) in the 12-week ARM-TD and AIM-TD studies. Objective: To evaluate the long-term safety and tolerab...